UK-1 and Structural Analogs Are Potent Inhibitors of Hepatitis C Virus Replication

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2013 Dec 24

PMID 24360997

Citations 3

Authors

Dawn N Ward

Daniel C Talley

Mrinalini Tavag

Samrawit Menji

Paul Schaughency

Andrea Baier

Paul J Smith

Affiliations

Soon will be listed here.

Abstract

The bacterial natural product UK-1 and several structural analogs inhibit replication of the hepatitis C virus in the replicon assay, with IC50 values as low as 0.50 μM. The NS3 helicase has been identified as a possible target of inhibition for several of these compounds, while the remaining inhibitors act via an undetermined mechanism. Gel shift assays suggest that helicase inhibition is a direct result of inhibitor-enzyme binding as opposed to direct RNA binding, and the ATPase activity of NS3 is not affected. The syntheses and biological results are presented herein.

Citing Articles

Benzimidazole and Benzoxazole Zinc Chelators as Inhibitors of Metallo-β-Lactamase NDM-1.

Jackson A, Pinter T, Talley D, Baker-Agha A, Patel D, Smith P ChemMedChem. 2020; 16(4):654-661.

PMID: 33211374 PMC: 8114186. DOI: 10.1002/cmdc.202000607.

Iodine-Catalyzed Functionalization of Primary Aliphatic Amines to Oxazoles, 1,4-Oxazines, and Oxazinones.

Debnath S, Das T, Gayen S, Ghosh T, Maiti D ACS Omega. 2019; 4(23):20410-20422.

PMID: 31815245 PMC: 6894181. DOI: 10.1021/acsomega.9b03501.

Exploring the biocombinatorial potential of benzoxazoles: generation of novel caboxamycin derivatives.

Losada A, Mendez C, Salas J, Olano C Microb Cell Fact. 2017; 16(1):93.

PMID: 28545544 PMC: 5445379. DOI: 10.1186/s12934-017-0709-6.

References

Beran R, Lindenbach B, Pyle A . The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase. J Virol. 2009; 83(7):3268-75. PMC: 2655585. DOI: 10.1128/JVI.01849-08. View

Soriano V, Labarga P, Fernandez-Montero J, Benito J, Poveda E, Rallon N . The changing face of hepatitis C in the new era of direct-acting antivirals. Antiviral Res. 2012; 97(1):36-40. DOI: 10.1016/j.antiviral.2012.10.011. View

Sarrazin C, Kieffer T, Bartels D, Hanzelka B, Muh U, Welker M . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132(5):1767-77. DOI: 10.1053/j.gastro.2007.02.037. View

Lam A, Frick D . Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol. 2005; 80(1):404-11. PMC: 1317551. DOI: 10.1128/JVI.80.1.404-411.2006. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

Borowski P, Niebuhr A, Mueller O, Bretner M, Felczak K, Kulikowski T . Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme. J Virol. 2001; 75(7):3220-9. PMC: 114115. DOI: 10.1128/JVI.75.7.3220-3229.2001. View

Jarvis T, Newport J, von Hippel P . Stimulation of the processivity of the DNA polymerase of bacteriophage T4 by the polymerase accessory proteins. The role of ATP hydrolysis. J Biol Chem. 1991; 266(3):1830-40. View

Kumar D, Jacob M, Reynolds M, Kerwin S . Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorg Med Chem. 2002; 10(12):3997-4004. DOI: 10.1016/s0968-0896(02)00327-9. View

Sakamoto N, Watanabe M . New therapeutic approaches to hepatitis C virus. J Gastroenterol. 2009; 44(7):643-9. DOI: 10.1007/s00535-009-0084-0. View

10.

. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 2000; 6(1):35-47. View

11.

Belon C, Frick D . Fuel specificity of the hepatitis C virus NS3 helicase. J Mol Biol. 2009; 388(4):851-64. PMC: 2692962. DOI: 10.1016/j.jmb.2009.03.059. View

12.

Choo Q, Richman K, Han J, Berger K, Lee C, Dong C . Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991; 88(6):2451-5. PMC: 51250. DOI: 10.1073/pnas.88.6.2451. View

13.

Rajagopal V, Gurjar M, Levin M, Patel S . The protease domain increases the translocation stepping efficiency of the hepatitis C virus NS3-4A helicase. J Biol Chem. 2010; 285(23):17821-32. PMC: 2878546. DOI: 10.1074/jbc.M110.114785. View

14.

Lavanchy D . The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1:74-81. DOI: 10.1111/j.1478-3231.2008.01934.x. View

15.

Kolykhalov A, Mihalik K, Feinstone S, Rice C . Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol. 2000; 74(4):2046-51. PMC: 111684. DOI: 10.1128/jvi.74.4.2046-2051.2000. View

16.

Failla C, Tomei L, De Francesco R . Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol. 1994; 68(6):3753-60. PMC: 236880. DOI: 10.1128/JVI.68.6.3753-3760.1994. View

17.

Lauer G, Walker B . Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-52. DOI: 10.1056/NEJM200107053450107. View

18.

Wardell A, Errington W, Ciaramella G, Merson J, McGarvey M . Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein. J Gen Virol. 1999; 80 ( Pt 3):701-709. DOI: 10.1099/0022-1317-80-3-701. View

19.

Frick D . The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol. 2007; 9(1):1-20. PMC: 3571657. View

20.

Borowski P, Kuehl R, Mueller O, Hwang L, Schulze Zur Wiesch J, Schmitz H . Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus. Eur J Biochem. 1999; 266(3):715-23. DOI: 10.1046/j.1432-1327.1999.00854.x. View